Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
AssigneeADNP Kids Research Foundation
InventorsSandra SERMONE, Matthew Christopher DAVIS
Life of this patent
Estimating the term…
Abstract
The invention is directed to a method of increasing the expression of Activity-Dependent Neuroprotector Protein (ADNP) in at least one mammalian cell showing insufficient ADNP expression levels, comprising administering to the at least one mammalian cell an effective amount of ketamine or a combination of ketamine and ADNP-Derived Neuroprotective Peptide (NAP).
Claims19
1-20. (canceled)
A method of treating a condition related to an insufficient Activity-Dependent Neuroprotective Protein (ADNP) expression level, the method comprising administering an effective amount of ketamine to a human subject in need of treatment for the condition related to the insufficient ADNP expression level, wherein the effective amount of ketamine is administered about every three days or about every four days.
Dependencies are inferred from the claim text.